Pages that link to "Q27674567"
Jump to navigation
Jump to search
The following pages link to Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β (Q27674567):
Displaying 50 items.
- Current Research Therapeutic Strategies for Alzheimer's Disease Treatment (Q26765530) (← links)
- Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics (Q26822002) (← links)
- Immunotherapy for Alzheimer's disease: hoops and hurdles (Q26823877) (← links)
- Advances in Alzheimer's disease drug development (Q26849352) (← links)
- Profile of gantenerumab and its potential in the treatment of Alzheimer's disease (Q27027675) (← links)
- Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation (Q27676409) (← links)
- Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab (Q27684692) (← links)
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease (Q28005463) (← links)
- Immunotherapeutic approaches for Alzheimer's disease (Q28081278) (← links)
- An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice (Q30316057) (← links)
- Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease (Q30651551) (← links)
- Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer (Q33604583) (← links)
- Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases (Q33731321) (← links)
- A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease (Q33853280) (← links)
- Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice. (Q34091134) (← links)
- Activity-modulating monoclonal antibodies to the human serine protease HtrA3 provide novel insights into regulating HtrA proteolytic activities. (Q34232310) (← links)
- Amyloid-beta: a crucial factor in Alzheimer's disease. (Q34451907) (← links)
- Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies (Q34472054) (← links)
- Amyloid-ß-directed immunotherapy for Alzheimer's disease (Q34548700) (← links)
- Novel immunological approaches for the treatment of Alzheimer's disease (Q34562675) (← links)
- Tau aggregation and its interplay with amyloid-β. (Q35008256) (← links)
- Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials (Q35695716) (← links)
- Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system. (Q35723422) (← links)
- Advances in recent patent and clinical trial drug development for Alzheimer's disease (Q35738142) (← links)
- Electroacupuncture Reduces Aβ Production and BACE1 Expression in SAMP8 Mice (Q35898132) (← links)
- TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance (Q36073450) (← links)
- Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies (Q36181289) (← links)
- Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice. (Q36269285) (← links)
- Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders (Q36484413) (← links)
- Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression? (Q36711795) (← links)
- A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease (Q36850925) (← links)
- Advances in the development of vaccines for Alzheimer's disease (Q36965988) (← links)
- Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier (Q37312010) (← links)
- Pre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity (Q37360313) (← links)
- Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. (Q37504954) (← links)
- Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin (Q37519267) (← links)
- Amyloid-beta immunotherapy: the hope for Alzheimer disease? (Q37679265) (← links)
- Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments (Q37730984) (← links)
- Gantenerumab for the treatment of Alzheimer's disease (Q38009878) (← links)
- Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies (Q38079317) (← links)
- Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future (Q38161675) (← links)
- Open questions for Alzheimer's disease immunotherapy (Q38176097) (← links)
- Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease (Q38219981) (← links)
- Immunotherapy for Alzheimer's disease: past, present and future (Q38222750) (← links)
- Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. (Q38230384) (← links)
- Biometals and their therapeutic implications in Alzheimer's disease. (Q38263669) (← links)
- Dissecting Amyloid Beta Deposition Using Distinct Strains of the Neurotropic Parasite Toxoplasma gondii as a Novel Tool. (Q38619717) (← links)
- Developing therapeutic vaccines against Alzheimer's disease (Q38636151) (← links)
- Central nervous system myeloid cells as drug targets: current status and translational challenges (Q38658658) (← links)
- The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind (Q38769710) (← links)